Caveolin-1 (CAV1), a highly conserved membrane-associated protein, is a putative regulator of cellular transformation. CAV1 is localized in the plasmalemma, secretory vesicles, golgi, mitochondria, and endoplasmatic reticulum membrane, and associates with the microtubule cytoskeleton. Taxanes such as paclitaxel (Taxol) are potent anti-tumor agents that repress the dynamic instability of microtubules and arrest cells in the G2/M phase. Src phosphorylation of Tyr 14 on CAV1 regulates its cellular localization and function. We report that phosphorylation of CAV1 on Tyr 14 regulates paclitaxel-mediated apoptosis in MCF-7 breast cancer cells. Befitting its role as a multitasking molecule, we show that CAV1 sensitizes cells to apoptosis by regulating cell cycle progression and activation of the apoptotic signaling molecules BCL2, p53 and p21. We demonstrate that phosophorylated CAV1 triggers apoptosis by inactivating BCL2 and increasing mitochondrial permeability more efficiently than nonphosophorylated CAV1.
Furthermore, expression of p21, which correlates with taxane sensitivity, is regulated by CAV1 phosphorylation in a p53-dependent manner. Collectively, our findings underscore the importance of CAV1 phosphorylation in apoptosis and suggest that events that negate CAV1 tyrosine phosphorylation may contribute to anti-microtubule drug resistance.
Caveolin-1 (CAV1) is a 21-24 kDa protein and the prototype of a family of integral membrane proteins that associate with specific cholesterol-and sphingolipid-rich domains to form the structural foundation of membrane invaginations called caveolae. Caveolae act as sites of signal transduction in various cell types (1) . CAV1 is thought to regulate the activity of proteins such as Src kinases, epidermal growth factor (EGF) tyrosine kinase, Her2/neu (ErbB2) kinase, extracellular-signal-regulated kinase (ERK), H-Ras, eNOS and G proteins (1, 2) involved in survival pathways. In human breast tumors, CAV1 levels inversely correlate with tumor size (3) , and CAV1 expression reduces the growth of mouse mammary tumors and their spontaneous metastasis to lung and bone (4) . However, in breast cancer cell culture models, CAV1 is down regulated in non-invasive human breast cancer cells but up-regulated in cells with an invasive phenotype (5) (6) (7) .
Taxanes are potent anti-tumor agents that function by binding to the β subunits of tubulin and repressing the dynamic instability of spindles (8, 9) , activities that lead to cell cycle arrest in the G2/M phase (10) . Taxanes such as paclitaxel (taxol) or docetaxel (taxotere) are routinely used in the first-line treatment of metastatic breast, lung, ovarian, and digestive cancers (11) . In primary breast cancer, inclusion of taxane in adjuvant chemotherapy reduces the relative risk of recurrence and improves overall survival (12) .
Acquired resistance through cellular adaptations or mutations in neoplastic cells remains a major problem in chemotherapy. While taxanes are substrates for ABC transporters, other resistance mechanisms are clearly important (13) . Therefore, it is important to improve our understanding of the mechanisms of drug responsiveness and to identify better predictors of drug efficacy.
CAV1 is essential for the formation and movement of caveolae through the cytoplasm along microtubule tracks and it is localized in the microtubule-organizing center or pericentrosomal region in CHO cells (14) . These findings suggest an essential relationship between CAV1 and microtubules or microtubule-associated proteins and their function. Treatment with a cytostatic dose of paclitaxel blocks lung cancer cells in G2/M and causes an up-regulation of CAV1, implicating CAV1 in taxane-mediated cell death and perhaps drug resistance (15) (16) (17) (18) . However, the role of CAV1 function in cell death remains unclear. In macrophages, induction of apoptosis by different apoptotic agents such as simvastatin and camptothecin leads to a large increase in CAV1 expression. As an early event, this increase in CAV1 is independent of caspase activation or DNA fragmentation but is associated with the plasma membrane translocation of phosphatidylserine (PS) (19) .
Originally identified as a substrate for vSrc (20) , CAV1 is phosophorylated on Tyr 14 by c-Src (21) . Mounting evidence suggests that phosophorylated CAV1 regulates caveolae formation and function (21) (22) (23) (24) (25) .
The precise role of Src kinase in taxane-mediated cytotoxicity is unclear. Src can increase taxotere sensitivity by mediating downstream apoptotic events through BCL2 phosphorylation in v-Src transformed human gall bladder epithelial cells (26) . However, in human ovarian cancer cells, an inhibition of Src activity increases paclitaxelinduced cytotoxicity (27) . Thus, the precise role of CAV1, and particularly that of phospho-CAV1(Y14), in affecting breast cancer cell responsiveness to taxanes is unknown.
The current study was undertaken to determine whether CAV1 is involved in the cytotoxic and proapoptotic actions of paclitaxel in MCF-7 human breast adenocarcinoma cells. We overexpressed wild-type (wt), a phosphorylation-defective CAV1 mutant (Y14F), or empty vector (EV) in MCF-7 cells that normally express low levels of endogenous CAV1. The effects of wtCAV1, Y14F, or EV expression on cell growth, apoptosis, and p53/p21 transcription in response to low dose (10 nM) paclitaxel were analyzed. This study provides novel insights into the function of CAV1 in paclitaxel sensitivity and the role of phosphorylation on Tyr 14 in CAV1-mediated effects on mitochondrial permeability and apoptosis.
EXPERIMENTAL PROCEDURES
Cell culture and reagents. MCF-7 cells (obtained from the LCCC Tissue Culture Shared Resource) were cultured in improved minimal essential media (IMEM; Biofluids, Rockville, MD) supplemented with 5% fetal bovine serum (FBS). Cells were maintained in a humidified atmosphere at 37°C and 95% air/5% CO 2 . Paclitaxel was obtained from Sigma (St. Louis, MO) and was dissolved in ethanol (which was used as the vehicle control). PP2 was purchased from Calbiochem (San Diego, CA). All other reagents were obtained from Sigma unless otherwise indicated. Generation of stable cell lines. MCF-7 cells were grown to 50-60% confluence and transfected with either human wild type (wt) CAV1 or Y14 F14 phosphorylation-deficient mutant (Y14F) in pcDNA6 or the empty vector (EV) using the FuGENE6 transfection reagent (Roche Applied Sciences Mannheim, Germany). Medium was replaced 24 hours later with complete growth medium and the cells were allowed to grow for 5 days. Complete growth media containing blasticidin S HCl (Invitrogen, Carlsbad, CA) (10 µg/ml) was used for stable selection.
For Reaction. Primer for CAV1 (Hs00971716_m1) and the housekeeping gene ribosomal protein, large, P0 (RPLPO) (Hs99999902_m1) was purchased from Applied Biosystems (Foster City, CA). MCF-7 cell were allowed to grow to 60-70% confluence in 75 cm 2 flasks and were then treated with either different concentrations of paclitaxel (0nM, 10nM, 100nM) for 24 hours or 10 nM paclitaxel for 0, 24 and 48 hours. RNA was extracted using the TRIzol Reagent (Invitrogen), cleaned using the RNeasy Kit (Qiagen, Valencia, CA), and analyzed by the Agilent Bioanalyzer 2100 (Santa Clara, CA). About 1 µg of DNase I (Invitrogen) treated RNA was reverse-transcribed with SuperScript II Reverse Transcriptase (Invirtogen) using Oligo(dT) 16 (Applied Biosystems). Real-time absolute quantitative PCR for each cDNA sample and a standard curve were established using Taq Man PCR Mastermix in the presence of CAV1 primer or the internal control RPLP0 primer. Reaction (10 µl) were run in triplicated in 384-well plates on an ABI Prism 7900 HT Sequence Detection System using the protocol suggested by the manufacturer. The ratio of CAV1 induction was estimated in comparison with RPLPO expression; data presented were the mean + SE. Transfection of small interfering (si) RNA. Cells were plated in 12-well or 24-well plates in complete media and allowed to grow to 50% confluence.
Approximately, 100 nM p21 siRNA, p53 siRNA (Cell Signaling, Danvers, MA), CAV1 siRNA (Dharmacon, Lafayette, CO) or their respective control siRNA were transfected using the TransIT-siQUEST (Mirus, Madison, WI) transfection reagent according to the manufacturer's protocol. At 24 hours, 10 nM paclitaxel or vehicle was added to the siRNA transfected cells. Cells were lysed at 48 hours post-transfection and subjected to Western blot analysis or cell proliferation assay as described above. Statistical Analyses. Statistical analyses were performed using the Sigmastat software package (Jandel Scientific, SPSS, Chicago, IL). Where appropriate, protein expression, cell growth, and apoptosis were compared using Student's t test or ANOVA with a post hoc t test for multiple comparisons. Where several groups were compared with the same control, we used Dunnett's test. Differences were considered significant at p < 0.05; all tests were two-tailed.
RESULTS
Exposure to taxane increased CAV1 expression in MCF-7 cells. CAV1 expression is very low but remains detectable in MCF-7 human breast cancer cells. To evaluate the effect of paclitaxel on CAV1 expression, MCF-7 cells were grown to 50-70% confluence and treated with 10 nM paclitaxel for 0, 24, or 48 hours, or with vehicle alone, 10 nM, or 100 nM paclitaxel for 24 hours. Real-time PCR show a significant increase in CAV1 expression in MCF-7 cells within 24 hours or 48 hours following paclitaxel treatment compared to control (untreated) ( Fig  1A, p<0 .004, one-way ANOVA). Western blot analysis shows corresponding increase in CAV1 protein within 24 hours or 48 hours (Fig 1B) . Treatment of MCF-7 cells with 10 nM and 100 nM for 24 hours show a significant increase in both CAV1 transcription (Fig 1 C, p<0 .001, oneway ANOVA), and protein expression (Fig 1 D) compared to controls (vehicle). Thus, in MCF-7 cells, a significant induction of CAV1 occurs within 24 hours following treatment with 10 nM of paclitaxel. The induction of CAV1 following paclitaxel treatment suggests a role for CAV1 in drug responsiveness.
Moreover, attenuating levels of endogenous CAV1 in MCF-7 cells with siRNA correlates with reduction in paclitaxelinduced inhibition of cell growth (Fig 2 A and  B) .
Phosphorylation of CAV1 on Tyr 14 by Src is known to regulate CAV1 functions (21) (22) (23) (24) (25) . To show whether Src inactivation reduces paclitaxel-induced inhibition of cell growth, we used PP2 to inhibit Src activation as detected by phosphorylation on Tyr 418 by Western blot analysis (Fig 2 C) .
While CAV1 protein expression increases following treatment of MCF-7 cells with 10 nM paclitaxel, phospho-CAV1 (p-CAV1) is undetectable using our Western blot analysis protocol (for up to 50 µg of protein loading per gel). However, incubation of MCF-7 cells with 10 µM PP2 in addition to 10 nM paclitaxel significantly reduces the cell growth inhibition effect of paclitaxel compared to paclitaxel alone (Fig 2 D, p<0 .005). wtCAV1 expression enhanced paclitaxelinduced growth inhibition and cell cycle arrest at G2/M. To establish the functional relevance of CAV1 in paclitaxel sensitivity, we generated MCF-7 cell lines that stably express either the full-length wild-type CAV1 (MCF-7/wtCAV1), Y14 F phosphorylation-deficient (MCF-7/Y14F) or empty vector (MCF-7/EV) ( Fig 3A) . Expression levels of CAV1 in MCF-7/wtCAV1 and MCF-7/Y14F were measured by Western blot analysis using specific antibodies for CAV1 or p-CAV1. CAV1α contains residues 1-178 while CAV1β contains residues 32-178.
Since Tyr 14 is the principal substrate for Src kinase, only CAV1α undergoes tyrosine phosphorylation (28) . CAV1 is thought to interact with Src and inhibit its activation (2). While not fully inactive, Src kinase activity is decreased in untreated MCF-7/wtCAV1 cells compared with MCF-7/EV and MCF-7/Y14F cells (Fig 3A) .
Expression of CAV1 in MCF-7 cells can reduce the rate of proliferation (29) . Comparison of growth curves in basal medium shows a significant decrease in the rate of cell proliferation for MCF-7/wtCAV1 cells (p<0.05) at day 4 through day 6 compared to that for MCF-7/EV cells. In contrast, the difference in rates of proliferation between MCF-7/EV and MCF-7/Y14F cells is not significant (Fig 3B) . Cells were treated with paclitaxel to determine whether CAV1 tyrosine phosphorylation affects growth inhibition by the drug. MCF-7 cells expressing wtCAV1 are more sensitive than cells expressing either EV or Y14F (Fig 3C) . These data suggest that CAV1 phosphorylation on Tyr 14 plays a key role in paclitaxel-induced growth inhibition. Furthermore, the effects of CAV1 on paclitaxel-sensitivity are not simply a consequence of changes in the rate of proliferation; cells that have a higher rate of proliferation are generally more sensitive to cell cycle specific cytotoxic drugs like taxanes (30) . Additionally, we did not see any difference in the partitioning of caveolar and intercellular compartments following sub-cellular fractionation (data not shown) between wtCAV1 or the Y14F mutant expressing cell under control conditions or following paclitaxel treatment for 24 hours. Thus, in terms of paclitaxel sensitivity, caveolar localization is unlikely to account for any differences between MCF-7 cells expressing wtCAV1 and Y14F.
Taxanes stabilize microtubules and block sensitive cells in the G2/M cell cycle phase (31) . To determine whether CAV1 expression alters G2/M cell cycle arrest following treatment with paclitaxel, MCF7-EV, MCF7-wtCAV1, or MCF-7/Y14F cells were treated with either vehicle alone or 10 nM paclitaxel for 24 hours prior to FACS analysis of cell cycle distribution (Fig 4A) .
MCF-7/Y14F cells exhibit a significant increase (p<0.05) in the proportion of cells in the S-phase relative to MCF-7/EV. Following treatment with 10 nM paclitaxel, the percentage of cells arrested in the G2/M phase is significantly higher in MCF7-wtCAV1 compared to MCF-7/EV (p<0.05). In MCF-7/Y14F cells, the percentage of cells in the G2/M phase is comparable to that in MCF-7/EV cells (Fig 4B) . Thus, the taxane-induced decrease in cell proliferation in MCF7-wtCAV1 cells is likely to be a consequence of increased cell cycle arrest in G2/M phase.
To assess cellular morphology in vehicle (control) or drug treated cells, MCF-7/EV, MCF-7/wtCAV1 and MCF-7/Y14F cells were treated with either vehicle or 10 nM paclitaxel for 24 hours. Cells were fixed and, permeabilized and co-stained for both β-tubulin and CAV1.
In all three cell lines, vehicle treated cells displayed an organized tubulin network that excludes the nucleus and extends throughout the cytoplasm (Fig 4C) . After 24 hours paclitaxel treatment, microtubule disruption is more distinct in MCF-7 cells expressing wtCAV1 compared to MCF-7 cells expressing EV or Y14F, as evident from clusters of microtubules or asters in the respective cells (Fig 4D) . Increased apoptosis in MCF-7/wtCAV1 expressing cells in response to paclitaxel. Paclitaxel can induce apoptosis in some breast epithelial cells (32) . To determine whether CAV1 expression affects apoptosis, we treated MCF-7/EV, MCF-7/wtCAV1 and MCF-7/Y14F cells with 10 nM paclitaxel for 24 hours. Apoptosis was detected by flow cytometry after staining for FITC-conjugated Annexin V and for propidium iodide. At 10 nM paclitaxel for 24 hours, only 1% of the MCF-7/EV or MCF-7/Y14F cells undergo apoptosis, compared with 3% in MCF-7/wtCAV1 cells (p<0.05) (Fig 5A) . Additionally, cells were analyzed for apoptosis by Western blot analysis of anti-poly(ADP) ribose polymerase (PARP) cleavage to a 85-89 kDa fragment (Fig 5B) . Paclitaxel-induced PARP cleavage appears in MCF-7/wtCAV1 within 24 hours following drug treatment and is more pronounced at 48 hours relative to MCF-7/EV or MCF-7/Y14F cells. Although the PARP antibody (according to manufacturer) should detect only a single band for cleaved PARP, we detected a non-specific higher molecular band at approximately 100-110 kDa that did not accurately reflect levels of full-length PARP in our experiments. These findings suggest that tyrosine phosphorylation of CAV1 accelerates apoptosis in response to paclitaxel treatment and/or could be essential to signaling pathway(s) that are required for the induction of apoptosis.
Microtubule disruption following treatment with taxanes increases phosphorylation of BCL2(S 70 ) in the G2/M phase of the cell cycle, abrogating the normal anti-apoptotic function of BCL2 and initiating an apoptotic program in cycling cancer cells (33) . To determine whether activation of BCL2 phosphorylation correlates with the degree of apoptosis, Western blot analyses were done with whole cell lysates cells following treatment with vehicle or 10 nM paclitaxel for 24 or 48 hours. At 24 hours, we detect a significant increase in the level of BCL2(S 70 ) phosphorylation in MCF-7/wtCAV1 cells in comparison to MCF-7/EV cells (p<0.05). In cells expressing Y14FCAV1, the level of BCL2(S 70 ) phosphorylation remains comparable to cells expressing EV (Fig 6A) . Furthermore, measurement of mitochondrial permeability, which is tightly associated with the release of pro-death molecules into the cytoplasm, is significantly increased in MCF-7/wtCAV1 cells treated with paclitaxel in comparison to cells treated with vehicle alone (p=0.01; Fig 6B) . wtCAV1 regulates p53-dependent p21 induction following treatment with paclitaxel. Low dose (~10 nM) paclitaxel treatment can increase p21 synthesis through a p53-dependent pathway (34, 35) and CAV1 and p53 can induce each other in fibroblasts (36) . Inhibition of p53 expression with siRNA in MCF-7/wtCAV1 cells prevents paclitaxel induced p21 protein expression (Fig 7A, B, C) . Thus, in wtCAV1 expressing cells, induction of p21 following paclitaxel treatment is p53-dependent.
To determine how expression of CAV1 interferes with p53 activity, we transiently expressed MCF-7/EV, MCF-7/wtCAV1, and MCF-7/Y14F with a p53-responsive promoter-reporter construct. Following 24 hours treatment with paclitaxel, p53 responsive element activation is significantly decreased in MCF-7/wtCAV1 expressing cells relative to vehicle treated cells (Fig 7D, p=0.036 ): this activation remains unchanged in MCF-7/EV and MCF-7/Y14F cells relative to their respective controls.
MCF-7 cells express a functional p53, and treatment with paclitaxel enhances p53 expression and function as seen in an upregulation of p21 and changes in cell cycle progression and apoptosis. Induction of p21 confers resistance to the cytotoxic effects of taxanes in MCF-7 cells (37) . Transient transfection of a full-length p21 promoterreporter construct showed that p21 promoter activity in MCF-7/wtCAV1 cells corresponds with p53 responsive element activation under control or drug treatment conditions. In MCF-7/EV and MCF-7/Y14F cells, p21 promoter activity following vehicle or drug treatment remains unchanged, as also occurs with p53 transcriptional activation in these cells (Fig 7E) .
We measured the level of p53 and p21 protein expression in MCF-7/EV, MCF-7/wtCAV1 and MCF-7/Y14F cells. Within 24 and 48 hours of drug treatment, p53 and p21 protein levels increase in all the three cell lines (Fig 8A, B) . However, the increase in MCF-7/wtCAV1 cells is significantly lower at both 24 and 48 hours following drug treatment when compared to MCF-7/EV or MCF7-Y14FCAV1 cells (p<0.05). CAV1 protein expression in both MCF-7/wtCAV1 and MCF-7/Y14F expressing cells is increased at 48 hours following drug treatment. p53 can initiate both cell cycle arrest and apoptosis, and an inhibition of p53-dependent p21 induction may drive cells towards apoptosis (38) . These results suggest that in MCF-7/wtCAV1 cells, phosophorylated CAV1 on Tyr 14 regulates induction of p53 and p21 following treatment with paclitaxel and is key in initiating the proapoptotic signal upstream of both p53 and p21.
DISCUSSION
CAV1 is a versatile protein that has received increased attention in cancer because of its role in cell survival (39) . CAV1 proteins form the foundation of cholesterol-rich membrane microdomains called caveolae, within which CAV1 regulates the functions of various signaling proteins (1) . Among the multiple cellular events that are regulated by CAV1, regulation of tumorigenesis remains controversial. Alteration or modification of CAV1 expression is common in some transformed cells, and understanding the signaling pathways affected by CAV1 may provide novel insight into new cancer therapies. In the present study, we show that treatment with 10 nM paclitaxel increased CAV1 protein expression in MCF-7 breast cancer cells within 24 hours; MCF-7 cells express very low levels of CAV1 under basal conditions. Down regulation of CAV1 expression with siRNA correlated with decreased paclitaxel-induced growth inhibition. Regulation of CAV1 signaling has been correlated with Src-mediated tyrosine phosphorylation at Tyr 14 (21-25, 40, 41) . We show that preventing Src activation with PP2 reduced paclitaxel-induced growth inhibition. We found that expression of wtCAV1 but not the phosphorylation-deficient mutant, Y14F, augmented sensitivity to paclitaxel in MCF-7 cells, and that tyrosine phosphorylation at Tyr 14 is essential in mediating the molecular events leading to apoptosis.
Our results show that expression of wtCAV1, but not Y14F, increases the inhibition of cell growth following treatment with paclitaxel. The inhibition of cell proliferation was associated with an increase in the blockade of cell cycle progression in cells harboring wt-CAV1 and this association may explain the reduction in cell growth following paclitaxel treatment. Subsequent to treatment with taxanes, cells arrest in the G2/M-phase due to microtubule stabilization, an event followed by the onset of apoptosis. Thus, our observations imply an interplay between cytoskeletal integrity and nuclear transcriptional events. MCF-7 cells express very low levels of endogenous CAV1 and exhibit both a time and dose dependent upregulation of CAV1 in response to paclitaxel treatment. Since microtubules are involved in the distribution of CAV1 between the Gogli/ER system and caveolae (42) , interruption of CAV1 delivery by microtubule stabilization following paclitaxel treatment could trigger the cell to increase CAV1 expression.
The spatial requirement for CAV1 in taxane induced cell cycle arrest and subsequent cell death is currently being investigated in our laboratory.
Accumulating evidence suggests a possible role for CAV1 in the initiation of cell death. For example, CAV1 is up-regulated in A549 lung cancer cells in response to paclitaxel (15) and the induction of apoptosis by several agents can significantly increase CAV1 expression in some cells (18) .
Paclitaxelinduced apoptosis in MCF-7 cells, as shown by Annexin V staining and PARP cleavage, significantly increased in the presence of wt-CAV1. Phosphorylation/inactivation of BCL2, as induced by paclitaxel (43, 44) , is associated with G2/M cell cycle arrest (45) . Increased expression of phospho-BCL2(S 70 ) and mitochondrial permeability in MCF-7/wtCAV1 cells, when compared with MCF-7/Y14F cells, implies a role for CAV1 phosphorylation in affecting the mitochondrial-dependent, intrinsic apoptosis pathway in paclitaxel-induced cell death.
Clinical studies have shown that taxanecontaining regimens are associated with a statistically significant improvement in overall survival compared with nontaxane-containing regimens; however, these regimens are associated with leukopenia and neurotoxicity (46) . Considering the heterogeneity among individuals, it is essential to discover molecular biomarkers in breast cancer cells that could help improve the benefits of taxanes by increasing the efficacy-to-toxicity ratio. Tumors that show the highest degree of G2/M phase arrest, BCL2 phosphorylation, and low or absent p21 after drug treatment, should exhibit sensitivity to paclitaxel. BCL2, an anti-apoptotic protein, is transcriptionally regulated by factors such as p53 (47) . Paclitaxel induces p21 in both p53-wild type and p53-null cells (48) . While CAV1 may be a target in p53-dependent signaling (5, 49) , the significance of this interaction in apoptosis is unknown. Inhibition of p53 expression in MCF-7 cells expressing either wtCAV1, Y14F or EV prevented the induction of p21 following paclitaxel treatment (Fig 7A, B, C) . Thus, in cells with a functional p53, the contribution of CAV1 to paclitaxel-mediated cytotoxicity appears to be p53-dependent.
A significant decrease in p53-and p21-luciferase reporter construct activation was observed within 24 hours following treatment with paclitaxel in MCF-7/wtCAV1 cells (Fig 7  D, E) . In contrast to its role in cell cycle arrest, p21 can increase cell survival following paclitaxel treatment in MCF-7 cells, and inhibition of p21 can increase paclitaxel cytotoxicity in MCF-7 cells (37) .
Thus, expression of wt-CAV1 in MCF-7 cells may increase the rate of apoptosis in MCF-7/wtCAV1 cells by down-regulating p21 expression. To our knowledge, this is the first report showing that phosphorylation of CAV1 at Tyr 14 sensitizes cells to BCL2-mediated apoptosis in a p53/p21-dependent manner.
It is likely that sensitivity as well as resistance to taxanes is dependent on the function of a panel of genes rather than a single gene or pathway. Our data suggest that CAV1 could be an essential component of signal transduction in taxane-mediated cell death. Up-regulation of CAV1 protein following treatment with paclitaxel has prompted investigators to implicate it as a marker for cytotoxicity and cell death in lung cancer cells (15) . However, it is unclear how CAV1 regulates cellular events at the onset of apoptosis. Expression of a phosphorylation-deficient Y14F mutant failed to augment sensitivity to paclitaxel when compared with cells expressing wtCAV1 in MCF-7 cells. This observation emphasizes the role of events that regulate phosphorylation of CAV1 in taxane sensitivity.
Furthermore, CAV1 acts by regulating paclitaxel-induced apoptosis in a manner that is dependent upon p53/p21 signaling and suppression of BCL2. Thus, this study provides direct experimental evidence of the role of CAV1 and its phosphorylation at Tyr 14 in affecting sensitivity to paclitaxel in p53-wild type breast cancer cells. Further analyses of the involvement of CAV1-mediated signaling in the taxane responsiveness in breast cancer cells are underway in our laboratory and may prove to be important for predicting tumor response to chemotherapy with these drugs. (Fig 2 D, p<0 .005). 
